The company secures a Beta (Market Risk) of 1.34, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Medite Cancer will likely underperform. Medite Cancer Diagnostics right now secures a risk of 0.0%. Please verify Medite Cancer Diagnostics mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and day median price , to decide if Medite Cancer Diagnostics will be following its current price movements.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Medite Cancer Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable forward indicators, Medite Cancer is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Begin Period Cash Flow
108 K
Total Cashflows From Investing Activities
-134 K
Free Cash Flow
-3.7 M
Medite
Medite Cancer Relative Risk vs. Return Landscape
If you would invest 0.01 in Medite Cancer Diagnostics on September 26, 2025 and sell it today you would earn a total of 0.00 from holding Medite Cancer Diagnostics or generate 0.0% return on investment over 90 days. Medite Cancer Diagnostics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Medite, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Medite Cancer Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medite Cancer's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Medite Cancer Diagnostics, and traders can use it to determine the average amount a Medite Cancer's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
MDIT
Based on monthly moving average Medite Cancer is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medite Cancer by adding Medite Cancer to a well-diversified portfolio.
Medite Cancer Fundamentals Growth
Medite Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Medite Cancer, and Medite Cancer fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medite Pink Sheet performance.
Assessing Medite Cancer's fundamental ratios provides investors with valuable insights into Medite Cancer's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Medite Cancer is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Medite Cancer Diagnostics, Inc. operates as a medical technology company. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida. Medite Cancer operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 69 people.
Things to note about Medite Cancer Diagnostics performance evaluation
Checking the ongoing alerts about Medite Cancer for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Medite Cancer Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Medite Cancer generated a negative expected return over the last 90 days
Medite Cancer has some characteristics of a very speculative penny stock
Medite Cancer has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (6.81 M) with profit before overhead, payroll, taxes, and interest of 162 K.
Medite Cancer Diagnostics currently holds about 90 K in cash with (3.57 M) of positive cash flow from operations.
Evaluating Medite Cancer's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Medite Cancer's pink sheet performance include:
Analyzing Medite Cancer's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medite Cancer's stock is overvalued or undervalued compared to its peers.
Examining Medite Cancer's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Medite Cancer's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medite Cancer's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Medite Cancer's pink sheet. These opinions can provide insight into Medite Cancer's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Medite Cancer's pink sheet performance is not an exact science, and many factors can impact Medite Cancer's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Medite Pink Sheet Analysis
When running Medite Cancer's price analysis, check to measure Medite Cancer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medite Cancer is operating at the current time. Most of Medite Cancer's value examination focuses on studying past and present price action to predict the probability of Medite Cancer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medite Cancer's price. Additionally, you may evaluate how the addition of Medite Cancer to your portfolios can decrease your overall portfolio volatility.